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The interval required for haematological reconstitution following myelosuppressive chemotherapy can be reduced by the infusion of
autologous peripheral blood progenitor cells (PBPCs). When carboplatin (C) and paclitaxel (P) are followed by granulocyte colony-
stimulating factor (GCSF), multiple courses can be given at 10-day intervals with the autologous PBPCs from a unit of whole blood
with each cycle. We extended this approach and defined the dose-limiting toxicity and maximum-tolerated dose for the addition of
gemcitabine (G) to CP for patients (pts) with EOC in a phase I–II study of increasing doses of G (0, 800, 1000 and 1250mgm
 2)
over four cohorts with C at area under curve (AUC) 6, plus P at 175mgm
 23h
 1 every 10 days for six cycles. Granulocyte colony-
stimulating factor 5mgkg
 1day
 1 was given s.c. days 1–10 and 450ml whole blood was venesected before each treatment, stored
untreated at 41C and reinfused 24h later. In all, 17 patients with EOC either bulky stage IV or recurrent after treatment-free interval
412 months were treated over 30 months. Of the 17 patients, 13 completed six cycles (one patient stopped early with PD, three
with toxicity), interdose interval 9–28 (median 10) days. Delays occurred in four patients due to infection or malaise, and there were
no dose reductions. Haematological toxicity was not considered to be dose limiting. Febrile neutropenia was uncommon (2 patients),
but grade III/IV thrombocytopenia was seen across all cohorts. Treatment was not delayed for thrombocytopenia and no bleeding
complications occurred. Grade III transaminitis was seen in all patients in cohort 4 and grade IV toxicity, considered to be dose
limiting, occurred in one. Responses were observed at all dose levels with six CR, seven PR, three SD and one PD. Dose intense GCP
was deliverable over six cycles with manageable haematological toxicity, but with dose-limiting hepatic toxicity in cohort 4. The MTD
was gemcitabine 1000mgm
 2, carboplatin AUC 6, paclitaxel 175mgm
 2 given every 10 days for six cycles.
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Platinum compounds are the mainstay of treatment in advanced
epithelial ovarian cancer. Standard chemotherapy currently
comprises a platinum agent in combination with paclitaxel (based
on the results of GOG protocol 111 and the Intergroup Trial OV10,
although not supported by ICON 3 (McGuire et al, 1996; Harper,
1999; Piccart et al, 2000)). However, 5-year survival remains 30%
or less. It is hoped that improvements in survival can be achieved
by the use of newer drugs and employing novel methods of dose
intensification such as shortening the interval between treatments,
without introducing unacceptable toxicity.
Gemcitabine is a fluorine-substituted pyrimidine antimetabolite,
structurally similar to cytosine arabinoside, which exhibits wide-
spread antitumour effects both in vitro and in vivo. It becomes
incorporated into DNA, leading to DNA strand breaks (after
addition of a subsequent nucleotide) and also disturbance of DNA
repair mechanisms (Huang et al, 1991; Plunkett et al, 1996).
Studies suggest a synergism between gemcitabine and platinum
analogues (Bergman et al, 1996; van Moorsel et al, 1999), which is
thought to be due to gemcitabine’s effects on DNA repair and its
different toxicity profile (Aapro et al, 1998), thereby lending itself
to combination therapy. Phase I/II trials have shown that
gemcitabine has activity in advanced EOC in both chemo-naive
patients (Underhill et al, 2001) and those with disease resistant to
platinum and paclitaxel (Lund et al, 1994; Shapiro et al, 1996;
Friedlander et al, 1998). The combination of gemcitabine with
platinum and paclitaxel has already been reported to produce high
response rates in EOC, but with dose-limiting haematological
toxicity (Geertsen et al, 1999; Hansen et al, 1999a,b; Poole et al,
2001; Hansen, 2002).
The experience of dose intensification with conventional
marrow ablative high-dose therapy, often with single agents
(Ledermann et al, 2001), has not proven to be beneficial for most
patients. An alternative approach is to use multiple agents, with
known activity, at full dose, but with a short intercycle time
interval to prevent tumour recovery between treatments. The use
of granulocyte colony-stimulating factor (GCSF) alone has not
been sufficient to increase the dose intensity of standard multicycle
chemotherapy; however, when combined with the collection and
reinfusion of peripheral blood progenitor cells (PBPC), there can
be a doubling of dose intensity for carboplatin and paclitaxel
(Pettengell et al, 1995, 1999; Woll et al, 1995, 2001).
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lThis study was designed to investigate whether treatment of
advanced EOC, with gemcitabine, carboplatin and paclitaxel given
every 10 days for six cycles, can be tolerated with the support of
GCSF and PBPC from autologous transfusion. The primary
objectives were to define the maximum-tolerated dose (MTD)
and dose-limiting toxicities (DLT) of this combination and
schedule, using fixed doses of carboplatin and paclitaxel, with
escalation of the dose of gemcitabine and secondarily to evaluate
the response rate and duration of response following this
treatment.
MATERIALS AND METHODS
Patient characteristics
In all, 17 patients were enrolled into the study between February
2000 and June 2002. All had histologically proven EOC, were aged
18–65 years, performance status 0–2, with a life expectancy of 43
months. Other eligibility criteria were measurable or evaluable
disease by RECIST criteria, normal haematological function,
adequate renal function (GFR 460mlmin
 1) and hepatic function
(LFTs o2  ULN). Patients were either previously untreated with
stage IV or bulky unresectable stage III disease (10), or had
relapsed with a treatment-free interval of 41 year (7) (see Table 1).
Patients were excluded if there was a concurrent malignancy
(other than nonmelanoma skin cancer), central nervous system
metastases, presence of atypical red blood cell antibodies, hepatitis
B surface antigen or anti-hepatitis C antibodies, HIV 1 and 2
antibodies, a previous adverse reaction to carboplatin or paclitaxel
or contraindication to the use of platinum. The protocol was
reviewed by the institutional research ethics committee and all
patients gave written informed consent. The support for GCSF
costs was received from Amgen UK.
The pretreatment evaluation included a full history and physical
examination with all lesions measured by physical examination
confirmed by a second physician. Laboratory investigation
included full blood count, biochemical profile (to assess liver
and renal function) and assay of CA 125. Diagnostic imaging of
measurable lesions was by chest X-ray, computed tomography
(CT) or magnetic resonance imaging.
Study design
Treatment was given in five cohorts each comprising three
patients. Chemotherapy was administered, according to cohort,
on day 1 of a 10-day cycle, for six cycles. GCSF (5mgkg
 1) was
given subcutaneously on days 2–9. On day 10, 750ml of blood was
venesected immediately prior to the next cycle of chemotherapy
and stored unprocessed at 41C (according to standard guidelines
proposed by the British Committee for Standards in Haematology
Blood transfusion Task Force; Voak et al, 1993). The autologous
blood was reinfused at least 18h postchemotherapy on cycles 2–6
prior to recommencing GCSF (see Table 2 and Figure 1). No
prophylactic antibiotics were given. Intravenous antibiotics were
given for febrile neutropenia and blood product support was given
according to unit policy.
Dose escalation
The dose of gemcitabine was escalated through cohorts 1–4
according to Table 2. At each dose level, the first patient completed
the full cycle of treatment before the remaining patients were
entered in case of unexpected toxicity. Each cohort completed
treatment before escalation to the next dose level. The dose was
escalated until the MTD was reached. As haematological toxicity
was expected, this was defined as the dose at which two of three
patients experienced nonhaematological DLT. This was defined as
grade III or IV toxicity, according to National Cancer Institute
common toxicity criteria. If two of the three patients in a cohort
experienced DLT, a further three patients were recruited at the
same dose and MTD was established if DLT occurred in another
patient.
Response assessment
Computed tomography scans to assess response were carried out
after four cycles and 4 weeks after the sixth cycle. Treatment was
continued to six cycles provided there was no evidence of
progressive disease. CA 125 assays were also carried out at the
start of each cycle. Follow-up after completion of treatment was
monthly with physical examination and CA125, with radiological
investigations as indicated by these findings.
Statistical analysis
Means, medians and proportions were calculated as appropriate.
This is a descriptive study and no intergroup comparisons were
made.
Table 1 Patient characteristics
Number 17
Age (years), median 27–73 (56)
Histology
Serous 10
Adenocarcinoma 6
Clear cell 1
Stage
3
Biopsy only 1
Suboptimal debulk 4
Optimal debulk 2
4
Biopsy only 2
Suboptimal debulk 1
Recurrent 7
Table 2 GCPq10 chemotherapy regimen by cohort
Cohort 1 Cohort 2 Cohort 3 Cohort 4
Carboplatin day 1 AUC 6 AUC 6 AUC 6 AUC 6
Paclitaxel day 1 (mgm
 2) 175 175 175 175
Gemcitabine day 1 (mgm
 2) — 800 1000 1200
AUC¼area under curve.
CYCLE 2 
CT 
CT GCSF VSBT GCSF
1
2 3 4 5 6 7 8 9 
Day 
1  2  34  5  6789 2 3 4
0 1
VS BT  GCSF
CT 
Cycle 1  Cycle 3, etc.
BT   –   autologous blood transfusion 
CT   –   chemotherapy 
GCSF  –   granulocyte colony-stimulating factor 
VS   –   venesection 
Figure 1 Treatment overview.
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lRESULTS
In all, 17 patients were recruited into the study. Dose escalation of
gemcitabine was achieved up to 1250mgm
 2, together with
carboplatin area under curve (AUC) 6 and paclitaxel 175mgm
 2
every 10 days, for six cycles.
All six cycles of treatment were completed by 13 of the 17
patients (Table 3). One patient discontinued treatment after four
cycles due to progressive disease and three patients stopped
treatment early due to toxicity. All are included in the analysis on
an intention-to-treat basis.
The average cycle length was 10.5 days (range 9–28 days).
Standard dose intensity was taken as carboplatin AUC 6 q21 days,
paclitaxel 175mgm
 2 q21 days and gemcitabine 1250mgm
 2 day
1 and 8 q21 days. In comparison, we achieved double the dose
intensity of carboplatin AUC 5.04week
 1 and double the dose
intensity of paclitaxel 147mgm
 2week
 1, but only 1.01 times the
dose intensity of gemcitabine at 840mgm
 2week
 1 Dose reduc-
tions, due to nonhaematological toxicity, were necessary for two
patients. Four patients had delays due to infectious complications
or malaise, resulting in a total of six of the 93 (6%) delayed cycles
(Table 3).
Haematological toxicity was expected, detected either by day 10
blood count or by investigation of symptoms between treatment
cycles (Table 4).
Grade III or IV thrombocytopenia was the most prevalent
toxicity occurring in 20 of the 93 (22%) cycles. The median platelet
counts and ranges on day 10 were 214 (20–281), 106 (28–281), 71
(15–119), 70 (25–206) and 90 (7–306) for cohorts 1, 2, 3, 4 and 3
repeat, respectively.
Platelet transfusions were given for counts below 10. Treatment
was repeated on day 10 regardless of the platelet count and no
cumulative toxicity or bleeding complications occurred.
Grade III or IV neutropenia occurred in a total of five of 93 (5%)
cycles. The median day 10 neutrophil counts and ranges for
cohorts 1, 2, 3, 4 and 3 repeat were 10.2 (0.8–30.9), 9.5 (1.1–59.6),
17.5 (5.2–59.4) 18.8 (9.6–39.9) and 10.0 (3.6–52.3). Two patients
required admission with neutropenic sepsis. The first patient to
develop febrile neutropenia received treatment in cohort 2. As the
episode was uncomplicated, this was not considered to be a DLT.
The second patient discontinued treatment as a result of febrile
neutropenia after cycle 3 in the final cohort (cohort 3 repeat).
Nonhaematological toxicity is described in Tables 5 and 6, with
grade III malaise in 10 cycles, grade III GI toxicity in five cycles
and grade III dyspnoea in eight cycles (due to one patient
developing pneumonia and one patient having a pulmonary
embolus, that is, not directly due to drug-related pulmonary
toxicity). One patient developed a rash and another had an allergic
reaction to carboplatin, requiring adjustment in premedication
and a slower rate of infusion in subsequent cycles. No renal
toxicity was observed at any dose level.
Liver function abnormalities appeared related to the dose of
gemcitabine and were not seen in cohort 1 (Table 6). One patient
in each of cohorts 2 and 3 had a rise in alanine transaminase
(ALT), gamma glutamyl transpeptidase or alkaline phosphatase
(total of eight cycles) and all four patients in cohort 4 developed
abnormalities. Grade III toxicity was seen in four cycles (three
patients). Grade IV toxicity was seen in one patient, with 420
times upper limit of normal rise in ALT for 2 days, returning to
normal over 2 weeks, who also became jaundiced with a grade I
rise in bilirubin. Her hepatitis serology remained negative and
liver biopsy revealed nonspecific changes consistent with a drug-
induced hepatitis. Although the formal definition of DLT had not
been reached, it was decided, in view of the trend of increasing
liver toxicity, to return to cohort 3 for a further study. In the
repeated cohort 3, one patient experienced grade I or II hepatic
toxicity (two cycles), as seen previously.
All patients were evaluable for response (Table 7). Responses
were seen at all dose levels. Complete response was achieved in six
patients (35%) and a partial response in seven (41%). Three
patients had stable disease and progressive disease was seen in
one. The overall response rate was 76% (95% CI: 56–96%).
One patient died prior to completing treatment due to bowel
obstruction and postoperative complications with a normal full
blood count.
The median length of follow-up is now 20 (range 2.9–34.0)
months, with a progression-free survival of 11 (range 1.3–28.8)
months.
DISCUSSION
The results of this study demonstrate that it is feasible to combine
gemcitabine with carboplatin and paclitaxel and to dose intensify
by delivering treatment every 10 days, with appropriate haema-
tological support to achieve a dose intensification of 2.1 times
conventional carboplatin and paclitaxel doses, but only 1.01 times
the gemcitabine dose intensity because of dose-limiting hepatic
toxicity.
Table 3 Treatment delivery
Cohort
Cycle no.
(mean)
Cycle length –
days (mean)
Delayed
cycles (no.)
Dose reductions
(no.)
1 6 11.4 2 0
2 6 11.3 2 0
3 6 10.3 2 1
4 5 10.0 0 0
3 repeat 4.2 10.0 1 0
Table 4 Grade III/IV haematological toxicity
Grade III/IV
neutropenia
Grade III/IV
thrombocyctopenia
Cohort
Total no.
of cycles
No.
cycles
% Nadir No.
cycles
% Nadir
1 18 3 17% 0.0 3 17% 28
0.8 20
N/A 13
2 18 2 11% 0.1 3 17% 38
0.1 28
12
3 18 0 7 39% 15
21
7
8
18
45
5
4 21 0 3 14% 25
37
8
3 repeat 18 1 6% 0.1 4 22% 29
33
7
9
Total 93 6 6% 20 22%
N/A¼not available.
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lOvarian cancer is a chemosensitive condition and has therefore,
as with other chemosensitive tumours, generated considerable
interest in increasing cytotoxic dose intensity, with the aim of
curing more patients. To date, the experience with conventional
high-dose therapy in this disease has not been encouraging. In
particular, it is clear that patients with bulky disease do not benefit
from this form of treatment and only the subgroup of patients in
complete remission at the time of high-dose therapy has been
shown to have a survival advantage over those whose transplants
were carried out in partial remission or less (Ledermann et al,
2001). There may be a number of possible explanations for this.
Studies have often used single-agent cytotoxics, which have not
had a particularly high activity in epithelial ovarian cancer. Also,
even with bone marrow support, the recovery time following a
single marrow ablative therapy is necessarily lengthy, allowing for
tumour recovery during this period.
It may be that alternative models of dose intensification, using
combinations of more active agents, over short time intervals, may
be more effective and we have shown one such strategy to be
possible.
The combination of gemcitabine, carboplatin and paclitaxel has
been associated with high response rates, both in our study of
patients with bulky or recurrent disease and previous reports
(Geertsen et al, 1999; Hansen et al, 1999a,b; Poole et al, 2001;
Hansen, 2002). With conventional 3-weekly scheduling, however,
haematological toxicity is dose limiting. In order to dose intensify,
we have used this three-drug combination every 10 days, with
GCSF-driven haematopoietic stem cell support from whole blood.
Previous reports have shown a modest increase in dose intensity
(1.34) to be possible with the use of GCSF alone (Woll et al, 1995).
However, a doubling of dose intensity may be achieved by
collection and reinfusion of haematopoietic stem cells (Pettengell
et al, 1995). These can be collected in whole blood after GCSF
priming by venesection immediately prior to chemotherapy. They
may be stored, unprocessed at 41C for 48h prior to reinfusion,
allowing for a practical and straightforward procedure that does
not necessarily require an overnight hospital admission. The
optimal collection occurs around days 10–12 following carbopla-
tin and paclitaxel (Pettengell et al, 1999), hence the rationale for
our intercycle interval.
The incidence of febrile neutropenia was low at two of the 93
cycles and was not found to be dose dependent. The most common
toxicity was thrombocytopenia, which was seen across all cohorts.
However, following the experience of Pettengel et al, we did not
delay treatment for thrombocytopenia and saw no cumulative
toxicity, even though patients were treated with a platelet count as
low as 7 at the time of chemotherapy.
We had anticipated that bone marrow toxicity would be
common with this regimen, but found that with PBSC support
we were not restricted by what would be considered to be
conventional dose-limiting haematological toxicity. In addition,
patients who have subsequently relapsed have been able to receive
further cytotoxic chemotherapy without bone marrow compro-
mise.
It appears from our study that the dose of gemcitabine, in
combination with platinum and paclitaxel, cannot be escalated
above 1000mgm
 2 every 10 days, owing to hepatic toxicity. Phase
I studies have suggested that gemcitabine, scheduled weekly for 3
weeks out of every 4, provides optimal activity (Allerheiligen et al,
1994; Fossella et al, 1997). In terms of toxicity, most data are
available with gemcitabine as a single agent, given according to the
above schedule in doses ranging from 800 to 1250mgm
 2.
Transient elevations in serum transaminases are well described,
occurring in approximately half of all patients; however, grade III/
IV toxicity is uncommon, occurring in o10% of patients. There
have been two case reports in the literature of mortality from liver
failure attributed to gemcitabine administration after other causes
were ruled out (Dobbie et al, 1998; Coeman et al, 2000). Although
most reports suggest transient toxicity, unrelated to the total
cumulative dose or duration of exposure to gemcitabine, both
fatalities occurred in patients who had undergone treatment for at
least 15 weeks. Our own observations certainly support a dose
effect, with grade III/IV toxicity only occurring at doses
41000mgm
 2. It is difficult to extrapolate these data entirely,
as we do not know the influence of the other drugs and our
different schedule on hepatic toxicity. It is likely that higher doses
cannot be tolerated at 10-day intervals for protracted periods.
In conclusion, while dose intensification was possible with
paclitaxel and carboplatin, we were not able to increase the dose
intensity of gemcitabine due to hepatic toxicity. The thrombocy-
Table 5 Other grade III/IV nonhaematological toxicity
Cohort Total no. of cycles given Infection cycles (%) GI cycles (%) Malaise cycles (%) Dyspnoea cycles (%)
1 18 1 (6%) 0 (0%) 2 (11%) 0 (0%)
2 18 0 (0%) 0 (0%) 0 (0%) 4 (22%)
3 18 0 (0%) 4 (22%) 4 (22%) 4 (22%)
4 21 0 (0%) 1 (5%) 2 (10%) 0 (0%)
3 repeat 18 1 (6%) 0 (0%) 3 (17%) 0 (0%)
Total 93 2 (2%) 5 (5%) 11 (12%) 8 (9%)
Table 6 Hepatic toxicity – all grades
Cohort Total no. of cycles Toxicity no. of cycles (%) Grade
11 80 0 %
2 18 3 17% I/II
3 18 5 28% I/II
4 21 7 33% I/II
5 24% III/IV
3 repeat 18 2 11% I/II
Total 93 22 24%
Table 7 Outcome
Cohort CR PR SD PD
11 2 — —
2— 2 1 —
32 1 — —
42 1 — 1
3 repeat 1 1 2 —
Total: six CR, seven PR, three SD, one PD, overall response rate 13 of the 17 – 76%.
CR¼complete response, PR¼partial response, SD¼stable disease, PD¼
progressive disease, by RECIST criteria.
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ltopenia was manageable with PBSC support, but makes this
regimen unlikely to be applied outside the research setting because
of the risk of bleeding, particularly if combined with other
predisposing factors. However, early intensification has been
shown to be important in other tumour types and perhaps with
the advent of potential maintenance therapies in ovarian cancer,
such as weekly taxol, angiogenesis inhibitors and signal transduc-
tion modulators, dose intense multiagent treatment could be
considered to provide remission induction prior to maintenance,
analogous to the treatment of acute leukaemia.
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